N_part	5000	Number_of_participants
EIR_equil	5e-04	equilibrium_EIR
P_occup	0.37	Prop_occupational_men
risk_occup	5	Occupational_risk_factor
start_time	2019	Start_time_in_years
end_time	2030	End_time_in_years
burnin_time	0	Burn_in_time_in_years
age_mean	11597	mean_population_age
age_max	29200	maximum_population_age
P_preg	0.075	Proportion_women_pregnant
age_0	2920	age-dependent_biting_parameter
rho_age	0.85	age-dependent_biting_parameter
sig_het	1.292285	heterogeneity_exposure
bb	0.5	human_to_mosquito_transmission
c_PCR	0.035	mosquito_to_human_transmission_PCR_detectable
c_LM	0.1	mosquito_to_huma_transmission_LM_detectable
c_D	0.8	mosquito_to_human_transmission_clinical_disease
c_T	0.4	mosquito_to_human_transmission_treatment
d_latent	10	latent_duration_in_liver
r_LM	0.1	LM_recovery_rate
r_D	0.2	clinical_disease_recovery
r_T	1	treatment_clearance_rate
d_PCR_min	10	duration_of_PCR_infection_full_immunity
d_PCR_max	70	duration_of_PCR_infection_no_immunity
A_PCR_50pc	9.9	anti_parasite_immunity_scale_parameter
K_PCR	4.602	anti_parasite_immunity_shape_parameter
u_par	19.77	anti_parasite_immunity_scale_paramter
r_par	0.0002739726	anti_parasite_immunity_decay
phi_LM_max	0.8918	prob_BS_infection_no_immunity
phi_LM_min	0.0043	prob_BS_infection_full_immunity
A_LM_50pc	27.52	BS_immunity_scale_parameter
K_LM	2.403	BS_immunity_shape_parameter
u_clin	7.85	clinical_immunity_scale_paramter
r_clin	9.13242e-05	clinical_immunity_decay
phi_D_max	0.8605	prob_clinical_episode_no_immunity
phi_D_min	0.018	prob_clinical_episode_max_immunity
A_D_50pc	11.538	clinical_immunity_scale_parameter
K_D	2.25	clinical_immunity_shape_parameter
P_mat	0.421	proportion_maternal_immunity
d_mat	35.148	maternal_immunity_decay
ff	0.01538462	relapse_rate
gamma_L	0.002610966	liver_clearance_rate
CM_regimen	1	treatment_regimen
CM_cover	0.95	proportion_of_symptomatic_cases_treated
CM_CQ_eff	0.899	chloroquine_treatment_efficacy
CM_CQ_eff_wPQ	0.946	chloroquine_treatment_efficacy_withPQ
CM_CQ_proph	28	chloroquine_treatment_prophylaxis
CM_PQ_eff	1	primaquine_efficacy
CM_PQ_proph	8	primaquine_prophylaxis
CM_PQ_adhere	1	primaquine_adherence
CM_PQ_lowage	180	minimum_age_primaquine
CM_PQ_G6PD_risk	1	G6PD_risk_for_primaquine
CM_PQ_CYP2D6_risk	1	CYP2D6_risk_for_primaquine
CM_PQ_preg_risk	1	G6PD_risk_for_pregnancy
CM_G6PD_test	1	G6PD_testing
G6PD_prev	0	Prevalence_of_G6PD_deficiency
mu_G6PD_nor	10.16	Mean_G6PD_activity_in_normals
sig_G6PD_nor	2.39	Standard_deviation_in_G6PD_activity_in_normals
mu_G6PD_het	4.6	Mean_G6PD_activity_in_heterozygous_deficients
sig_G6PD_het	1.67	Standard_deviation_in_G6PD_activity_in_heterozygous_deficients
mu_G6PD_def	0.48	Mean_G6PD_activity_in_homozygous_deficients
sig_G6PD_def	0.31	Standard_deviation_in_G6PD_activity_in_homozygous_deficients
CYP2D6_prev	0	Prevalence_of_CYP2D6_phenotype
rho_round_LLIN	0.5	correlation_between_LLIN_rounds
rho_round_IRS	0.8	correlation_between_IRS_rounds
rho_round_MDA	0.5	correlation_between_MDA_rounds
rho_LLIN_IRS	0.6	correlation_between_IRS_LLINS
rho_MDA_VC	0.2	correlation_between_MDA_vector_control
